Sunday September 20, 2020

updated - September 20, 2020 Sunday EDT

Valeant Announces Fulfillment Agreement With Walgreens, Boosts Credibility With Investors And Sends Shares Up

Dec 17, 2015 12:40 PM EST | By Jean-Claude Arnobit
Valeant Pharmaceuticals International Inc., Walgreens Boots Alliance, new fulfillment agreement
Valeant Announces Fulfillment Agreement with Walgreens, Boosts Credibility with Investors and Sent Shares Up
(Photo : Justin Sullivan | Getty Images News)

Valeant Pharmaceuticals International Inc. has announced in a press release that it has new fulfillment agreements with Walgreens Boots Alliance Inc., the largest drugstore chain in the U.S.

The agreement with Walgreens has boosted Valeant's credibility with wary investors, and sent its shares up 17 percent.

Reuters said Valeant and its chairman and CEO Michael Pearson have come under pressure for the steep price increases on some of the company's drugs.

Valeant is also reeling from its close ties to a specialty pharmacy that used aggressive methods to overcome insurer barriers to reimbursing its medicines.

The company's share prices have dropped nearly 75 percent in recent months as its actions came under scrutiny from Congress, the State, and federal regulators.

Valeant said that they will be reducing the prices of their branded prescription-based dermatological and ophthalmological products by 10 percent.

The reduced pricing applies to the wholesale list prices of these products and will be phased in over the next six to nine months.

David Larsen, an analyst for Leerink, said in a research note that Valeant "appears to be taking steps to appease some pricing scrutiny.

Valeant said that the 20-year agreement, which will take effect on the first quarter of 2016, is designed to create a more efficient model to help lower costs while ensuring patients have access to doctor-prescribed products.

The company also said that patients who have commercial insurance will be able to benefit from lower out-of-pocket costs, which is initially set to be as low as zero in some products.

Pearson said in the press release that the company has listened to "what the marketplace is saying" and has "taken positive steps to respond."

"Our goal is to create a system that allows prescription medications to be dispensed and insurance claims adjudicated in an efficient manner while allowing physicians to focus their efforts on what matters most: patient care," he said.

The cost-sharing program, though, will not be applicable to patients with government insurance due to government regulation.

Valeant also entered into a separate agreement with Walgreens where the company will distribute more than 30 branded products in the dermatology, ophthalmology, gastrointestinal and neurology/other therapeutic areas through Walgreens.

The company will be distributing these branded products where generics are available at generic prices, which will be available to all patients beginning in the second half of 2016.

Get the Most Popular Franchiseherald Stories in a Weekly Newsletter
© 2015 Franchise Herald. All rights reserved.
>>>>>>> 10460c7d066ded6bd40ea293096592303635a9b7 <<<<<<< HEAD ======= >>>>>>> 10460c7d066ded6bd40ea293096592303635a9b7
<<<<<<< HEAD ======= >>>>>>> 10460c7d066ded6bd40ea293096592303635a9b7

Connect With Franchise News

Email Newsletter


  • RANK
  • 1nc
    Hampton Hotels
    $3.7M - 13.52M
  • 2nc
    $85.2K - 260.35K
  • 3up
    Jiffy Lube Int'l. Inc.
    $196.5K - 304K
  • 4down
    7-Eleven Inc.
    $30.8K - 1.64M
  • 5up
    $103.55K - 196.5K
  • 6up
    Anytime Fitness
    $56.3K - 353.9K
  • 7down
    $133.05K - 181.45K
  • 8down
    Denny's Inc.
    $1.18M - 2.4M
  • 9down
    $1M - 2.16M
  • 10down
    Pizza Hut Inc.
    $295K - 2.15M
Real Time Analytics